PAI-1 and Diabetes: A Journey From the Bench to the Bedside
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
D iabetologists have been well awaresince the seminal work ofHimsworth(1) in the 1930s that type 2 (insu-lin resistant) and type 1 (insulin defi-cient) diabetes were distinct entities with different pathophysiological bases. They have been aware for some time that type 2 diabetes is associated with resistance of tissues such as muscle and liver to the biological effects of in-sulin. Furthermore, they knew that type 2 diabetes per se and insulin resistance could both predispose to an increased risk of premature coronary artery dis-ease and particularly the premature oc-currence of myocardial infarction (MI). By contrast, cardiologists came to em-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another prominent SASP component, PAI-1, is increased in the circulation and tissues, such as coronary arteries of patients with diabetes (57).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Alessi, M. C., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 615 · cited 1×
“Adipose tissue expresses PAI-1 (23) and may be a particularly important source of PAI-1 in blood in obese subjects.”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Self-citationVague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M. C., & Collen, D. (1986) · Metabolism · doi:10.1016/0026-0495(86)90209-x · Cited by 443
Werf, F. V. D., Ludbrook, P. A., Bergmann, S. R., Tiefenbrunn, A. J., Fox, K. A. A., Geest, H. D., Verstraete, M., Collen, D., & Sobel, B. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403083101001 · Cited by 358
Self-citationFactors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients
McGill, J. B., Schneider, D. J., Arfken, C. L., Lucore, C. L., & Sobel, B. E. (1994) · Diabetes · doi:10.2337/diab.43.1.104 · Cited by 310
Self-citationAlessi, M. C., Juhan-Vague, I., Kooistra, T., Declerck, P. J., & Collen, D. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646997 · Cited by 289 · cited 2×
“Triglycerides and their constituents (fatty acids) increase the expression of PAI-1 in HepG2 cells (15).”
BackgroundTissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Auwerx, J., Bouillon, R., Collen, D., & Geboers, J. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.68 · Cited by 276 · cited 1×
“Results of studies in vivo linking diabetes and insulin resistance to increased expression of PAI-1dElevated concentrations of PAI-1 have been observed consistently in blood from patients with diabetes, particularly those with type 2 diabetes (17).”
BackgroundSmith, S. C., Jr. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/fqnb-n505 · Cited by 273
Sobel, B. E., Woodcock-Mitchell, J., Schneider, D. J., Holt, R. E., Marutsuka, K., & Gold, H. (1998) · Circulation · doi:10.1161/01.cir.97.22.2213 · Cited by 271
Self-citationChaitman, B. R., Hardison, R. M., Adler, D., Gebhart, S., Grogan, M., Ocampo, S., Sopko, G., Ramires, J. A., Schneider, D., Frye, R. L., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.913111 · Cited by 263
Self-citationJuhan-Vague, I., Vague, P., Alessi, M., Badier, C., Valadier, J., Aillaud, M.-F., & Atlan, C. (1987) · PubMed · Cited by 218
Chen, Y.-Q., Su, M., Walia, R. R., Hao, Q., Covington, J. W., & Vaughan, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.8225 · Cited by 217 · cited 1×
“Elevated concentrations of glucose increase expression of PAI-1 by both endothelial cells and VSM cells in vitro (14).”
BackgroundLiu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187 · cited 1×
“Agonists of glucagon-like peptide-1, such as liraglutide, inhibit induction of PAI-1 mediated by tumor necrosis factor-a or hyperglycemia (40).”
BackgroundSampson, M., Kong, C., Patel, A., Unwin, R., & Jacobs, H. S. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00863.x · Cited by 186 · cited 1×
“Other conditions associated with insulin resistance such as hypertension (18) and polycystic ovarian syndrome (19) are associated with increased concentrations of PAI-1 in blood as well (Table 1).”
BackgroundInduction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo
Nordt, T. K., Sawa, H., Fujii, S., & Sobel, B. E. (1995) · Circulation · doi:10.1161/01.cir.91.3.764 · Cited by 185
Self-citationKruszynska, Y. T., Yu, J. G., Olefsky, J. M., & Sobel, B. E. (2000) · Diabetes · doi:10.2337/diabetes.49.4.633 · Cited by 185 · cited 1×
“These agents decrease PAI-1 in patients with type 2 diabetes (38) and subjects with insulin-resistant states (38,39) to the extent that they improve glycemic control and reduce hyperinsulinemia.”
BackgroundSelf-citationSchneider, D. J., & Sobel, B. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9959 · Cited by 161 · cited 1×
“The effects of insulin were increased synergistically by the combination of insulin plus insulin-like growth factor 1 (9).”
BackgroundSelf-citationIncreased Plasminogen Activator Inhibitor-1 and Vasculopathy: A Reconcilable Paradox
Sobel, B. E. (1999) · Circulation · doi:10.1161/01.cir.99.19.2496 · Cited by 159
Self-citationNordt, T. K., Schneider, D. J., & Sobel, B. E. (1994) · Circulation · doi:10.1161/01.cir.89.1.321 · Cited by 159 · cited 1×
“In addition, precursors of insulin, both proinsulin and split products of proinsulin, concentrations of which are known to be elevated in blood from patients with type 2 diabetes, augment the expression of PAI-1 (10).”
BackgroundSelf-citationPandolfi, A., Cetrullo, D., Polishuck, R., Alberta, M. M., Calafiore, A., Pellegrini, G., Vitacolonna, E., Capani, F., & Consoli, A. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0801.093667 · Cited by 156 · cited 1×
“(22) examined the internal mammary arteries from patients with type 2 diabetes and found amarked increase in active PAI-1.”
BackgroundCalles-Escandon, J., Mirza, S. A., Sobel, B. E., & Schneider, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.290 · Cited by 147 · cited 1×
“Furthermore, systemic infusion of a combination of insulin, glucose, and aliposyn to simulate hypertriglyceridemia and insulin resistance was sufficient to increase expression of PAI-1 in healthy, normal human subjects (28).”
BackgroundSelf-citationPandolfi, A., Giaccari, A., Cilli, C., Alberta, M. M., Morviducci, L., De Filippis, E. A., Buongiorno, A., Pellegrini, G., Capani, G., & Consoli, A. (2001) · Acta Diabetologica · doi:10.1007/s005920170016 · Cited by 144 · cited 1×
“Similarly, acute hyperglycemia and hyperinsulinemia increased the concentration and activity of PAI-1 in blood from rats (26).”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199801000-00017 · Cited by 132
Self-citationPatency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-Up
BELLE, E. V., Ketelers, R., Bauters, C., Périé, M., Abolmaali, K., Richard, F., Lablanche, J., McFadden, E. P., & Bertrand, M. E. (2001) · Circulation · doi:10.1161/01.cir.103.9.1218 · Cited by 121 · cited 1×
“This phenomenon may explain in part the well-recognized increased propensity of patients with type 2 diabetes who are subjected to PCI to develop restenosis in an accelerated fashion compared with that seen in patients without diabetes (33).”
ResultFattal, P. G., Schneider, D. J., Sobel, B. E., & Billadello, J. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42289-2 · Cited by 103 · cited 1×
“Results in mechanistic studies that we performed demonstrated that insulin reduced the rate of degradation of PAI-1 mRNA (11).”
BackgroundSelf-citationBrooks, M. M., Frye, R. L., GENUTH, S. M., Detre, K. M., Nesto, R. W., Sobel, B. E., Kelsey, S. F., & Orchard, T. J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.023 · Cited by 101 · cited 1×
“Results in the BARI 2D trialdThe Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was undertaken to test two null hypotheses in patients with type 2 diabetes (42).”
BackgroundSelf-citationWhy Does Ethnicity Affect Prevalence of Gestational Diabetes? The Underwater Volcano Theory
Yue, D. K., Molyneaux, L. M., Ross, G. P., Constantino, M. I., Child, A. G., & Turtle, J. R. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199608)13:8<748::aid-dia164>3.0.co;2-i · Cited by 101
Chen, Y., Budd, R. C., Kelm, R. J., Sobel, B. E., & Schneider, D. J. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000227514.50065.2a · Cited by 97 · cited 1×
“In fact, by overexpressing PAI-1 in VSM cells and characterizing their response to chemotactic factors, we showed that proliferation (32) was, in fact, a consequence of the increased expression of PAI-1.”
BackgroundSelf-citationHypofibrinolysis in patients with hypertension and elevated cholesterol
Jansson, J., Johansson, B. H., Boman, K., & Nilsson, T. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00352.x · Cited by 92 · cited 1×
“Other conditions associated with insulin resistance such as hypertension (18) and polycystic ovarian syndrome (19) are associated with increased concentrations of PAI-1 in blood as well (Table 1).”
BackgroundSobel, B. E., Hardison, R. M., Genuth, S., Brooks, M. M., McBane, R. D., Schneider, D. J., Pratley, R. E., Huber, K., Wolk, R., Krishnaswami, A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.014860 · Cited by 78 · cited 2×
“overall treatment interval of 5 years in the BARI 2D trial (44).”
BackgroundSelf-citationPandolfi, A., Iacoviello, L., Capani, F., Vitacolonna, E., Donati, M. B., & Consoli, A. (1996) · Diabetologia · doi:10.1007/s001250050594 · Cited by 76 · cited 1×
“Augmented expression of PAI-1 was seen also in VSM cells in culture (13) in response to insulin and with cocultured endothelial cells and smooth muscle cells (12).”
BackgroundKrysiak, R., Gdula-Dymek, A., Bachowski, R., & Okopień, B. (2010) · Diabetes Care · doi:10.2337/dc10-0272 · Cited by 69 · cited 1×
“Agents that decrease concentrations of triglycerides in blood such as atorvastatin and gemfibrozil reduce concentrations of PAI-1 in blood from patients with insulin-resistant states (41).”
BackgroundCefalu, W. T., Schneider, D. J., Carlson, H. E., Migdal, P., Gan Lim, L., Izon, M. P., Kapoor, A., Bell-Farrow, A., Terry, J. G., & Sobel, B. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2123 · Cited by 65
Self-citationSchneider, D. J., & Sobel, B. E. (1996) · Coronary Artery Disease · doi:10.1097/00019501-199611000-00004 · Cited by 63 · cited 1×
“Moreover, the combination of elevated concentrations of both insulin and triglycerides exerts a synergistic increase in accumulation of PAI-1 in conditioned media of such cells (16).”
BackgroundSelf-citationThe effect of plasminogen activator inhibitor type 1 on apoptosis
Chen, Y., Sobel, B. E., & Schneider, D. J. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0234 · Cited by 59 · cited 1×
“proliferation,we studied the effects of PAI-1 on the caspase system, known to be instrumental in a final common pathway leading to apoptosis (31).”
BackgroundSelf-citationPotentiation of Vasculopathy by Insulin: Implications From an NHLBI Clinical Alert
Sobel, B. E. (1996) · Circulation · doi:10.1161/01.cir.93.9.1613 · Cited by 52 · cited 1×
“The observations led to an issuance of a clinical alert by the National Institutes of Health pointing out that PTCA may be deleterious in patients with type 2 diabetes (30).”
BackgroundSelf-citationSchneider, D. J., Absher, P. M., & Ricci, M. A. (1997) · Circulation · doi:10.1161/01.cir.96.9.2868 · Cited by 52 · cited 2×
“Augmented expression of PAI-1 was seen also in VSM cells in culture (13) in response to insulin and with cocultured endothelial cells and smooth muscle cells (12).”
BackgroundSelf-citationChen, Y., Billadello, J. J., & Schneider, D. J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.12.2696 · Cited by 52 · cited 1×
“Triglycerides and their constituents (fatty acids) increase the expression of PAI-1 in HepG2 cells (15).”
BackgroundSelf-citationBelalcazar, L. M., Ballantyne, C. M., Lang, W., Haffner, S. M., Rushing, J., Schwenke, D. C., Pi-Sunyer, X., & Tracy, R. P. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.224386 · Cited by 49 · cited 1×
“Caloric restriction and exercise diminish insulin resistance, decrease hyperinsulinemia, improve glycemic control, and decrease concentrations of PAI-1 in blood (37).”
Schneider, D. J., Hayes, M., Wadsworth, M. P., Taatjes‐Sommer, H. S., Rincón, M., Taatjes, D. J., & Sobel, B. E. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.4a6260.2004 · Cited by 47 · cited 1×
“We speculated that increased PAI-1 in vessel walls would predispose to acceleration of atherosclerosis and development of plaques with specific characteristics rendering them vulnerable to rupture (29).”
BackgroundSelf-citationPlasminogen Activator Inhibitor-1 Overexpression in Nonproliferative Diabetic Retinopathy
Grant, M. B., Ellis, E. A., Caballero, S., & Mames, R. N. (1996) · Experimental Eye Research · doi:10.1006/exer.1996.0112 · Cited by 39 · cited 1×
“Immunohistochemical examinations of retinas demonstrated that endothelial cells from patients with type 2 diabetes express significantly greater amounts of PAI-1 (24).”
BackgroundNagi, D. K., Ali, V. M., & Yudkin, J. S. (1996) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199608)13:8<753::aid-dia163>3.0.co;2-z · Cited by 37
Carmassi, F., Morale, M., Ferrini, L., Dell’Omo, G., Ferdeghini, M., Pedrinelli, R., & Negri, F. D. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00240-5 · Cited by 36 · cited 1×
“However, localized intra-arterial infusion of insulin led to a marked increase in the concentration of PAI-1 in blood and induced impaired fibrinolysis (27).”
BackgroundThe effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects.
Grant, P. J. (1991) · PubMed · Cited by 30
Methyldopa and propranolol or practolol in moderate hypertension.
Petrie, J. C., Galloway, D. B., Jeffers, T. A., Millar, H. R., Smith, M. C., Wood, R. A., Lewis, J., & Simpson, W. (1976) · BMJ · doi:10.1136/bmj.2.6028.137 · Cited by 19
MANAGEMENT OF DIABETES MELLITUS
Himsworth, H. P. (1936) · BMJ · doi:10.1136/bmj.2.3941.137 · Cited by 14
Management of Diabetes Mellitus
Nather, A., Ho, S., & Quah, Y. L. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814417013_0004 · Cited by 7
Cited by
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
“Another prominent SASP component, PAI-1, is increased in the circulation and tissues, such as coronary arteries of patients with diabetes (57).”
BackgroundHemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation
Spronk, E., Sykes, G., Falcione, S., Munsterman, D., Joy, T., Kamtchum-Tatuene, J., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.661955 · Cited by 225
Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets
Pechlivani, N., & Ajjan, R. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00001 · Cited by 197
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
“Hormonal (hyperinsulinemia) and metabolic (hyperglycemia and hypertriglyceridemia) derangements, typically found in T2DM patients, seem to have a role in elevated levels of PAI-1 levels in this population [130].”
BackgroundDiabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
Jia, G., Bai, H., Mather, B., Hill, M. A., Jia, G., & Sowers, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020804 · Cited by 135
“On the one hand, insulin resistance increases plasminogen activator inhibitor-1 (PAI-1) and fibrinogen while decreasing tissue plasminogen activator levels [66].”
BackgroundInfluential
Metadata
- Authors
- Schneider, D. J., & Sobel, B. E.
- Affiliations
- University of Vermont (US)
- Corresponding author
- Schneider, David J.
- ORCID
- Schneider, David J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-09-11
- Volume
- 35
- Issue
- 10
- Pages
- 1961-1967
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3447837
- OpenAlex
- W1974895405
- Cited by
- 78
- References
- 50
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 8 · 2014: 1 · 2013: 9 · 2012: 2
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- plasminogen activator inhibitor-1, type 2 diabetes, type 1 diabetes, insulin resistance, myocardial infarction, coronary artery disease, cardiovascular risk, thrombosis
- MeSH terms
- Animals, Coronary Artery Bypass, Coronary Artery Disease, Diabetes Mellitus, Type 2, Fibrinolysis, Humans, Insulin, Insulin Resistance, Male, Myocardial Infarction, Obesity, Tissue Plasminogen Activator, Rabbits, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Plasminogen Activator Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.